Surface Oncology, Inc.
SURF · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $30 | $3 | $126 | $15 |
| % Growth | 1,016.5% | -97.9% | 721.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $30 | $3 | $126 | $15 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $67 | $54 | $41 | $52 |
| G&A Expenses | $25 | $25 | $24 | $21 |
| SG&A Expenses | $25 | $25 | $24 | $21 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $92 | $79 | $65 | $73 |
| Operating Income | -$62 | -$76 | $62 | -$57 |
| % Margin | -206.2% | -2,828.9% | 48.8% | -373.5% |
| Other Income/Exp. Net | -$2 | -$2 | -$2 | $3 |
| Pre-Tax Income | -$64 | -$78 | $59 | -$55 |
| Tax Expense | $2 | $1 | $0 | -$2 |
| Net Income | -$65 | -$79 | $59 | -$53 |
| % Margin | -217.7% | -2,957.3% | 47% | -345.1% |
| EPS | -1.17 | -1.8 | 1.67 | -1.9 |
| % Growth | 35% | -207.8% | 187.9% | – |
| EPS Diluted | -1.17 | -1.8 | 1.57 | -1.9 |
| Weighted Avg Shares Out | 56 | 44 | 38 | 28 |
| Weighted Avg Shares Out Dil | 56 | 44 | 38 | 28 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $3 |
| Interest Expense | $2 | $2 | $2 | $0 |
| Depreciation & Amortization | $1 | $2 | $2 | $2 |
| EBITDA | -$62 | -$76 | $62 | -$57 |
| % Margin | -206.2% | -2,828.9% | 48.8% | -373.5% |